2013 CPT Code Change to be Discussed at the Evidence-Based Reimbursement Summit

Oct. 18, 2012 - PRLog -- NEEDHAM, MASS. – In recent weeks, The American Medical Association has made updates to the 2013 Current Procedural Terminology (CPT) code set1. These changes will have a notable impact on Medicare, Medicaid, as well as private insurances policies.

The inaugural Evidence-Based Reimbursement Summit (November 5-7, 2012 in Philadelphia, PA) aims to be the preeminent event for all major stakeholders in the field of evidence-based reimbursement in pharma and diagnostics, government affairs, health care economics, and clinical development.

A dedicated session on the 2013 CPT Code Changes will feature presentations from Danielle Scelfo, Director, Government Affairs, Genomic Health, Karl Florence, Director of Reimbursement, Vermillion, Roger D. Klein, M.D., J.D., Pathologist, Department of Molecular Pathology, Cleveland Clinic Foundation, and Laura Sullivan, Vice President, Customer Care & Reimbursement, Good Start Genetics.

Topics to be discussed include Coverage Coding and Reimbursement in Advanced Molecular Diagnostics, CPT Code Application-The New Reality of a CPT Code Change, Coding and Reimbursement for Molecular Testing: New Developments and Interesting Times Ahead, Next-Generation Sequencing and the Reimbursement Landscape, and a panel discussion focusing on both the upside and downside to the new changes.

In addition to CPT Code Change, The Evidence-Based Reimbursement Summit will delve into topics including product development strategies, generating real world data, personalized medicine / companion diagnostics, and more.  For full details visit www.Healthtech.com/Evidence-Based-Reimbursement-Summit.

Source
1) http://www.ama-assn.org/ama/pub/amawire/2012-september-26...

About Cambridge Healthtech Institute (www.chicorporate.com)
Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Barnett International, Cambridge Marketing Consultants, Cambridge Meeting Planners and Cambridge Healthtech’s Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.
Founded in 1992, Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business.

Contact:
Pete DeOlympio
Marketing Manager
Cambridge Healthtech Institute
peted@healthtech.com